<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14 CLINICAL STUDIES<BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.1 Atrial Fibrillation<BR>                     <BR>                        In five prospective, randomized, controlled clinical trials involving 3711 patients with nonrheumatic AF, warfarin significantly reduced the risk of systemic thromboembolism including stroke (see Table 4). The risk reduction ranged from 60% to 86% in all except one trial (CAFA: 45%), which was stopped early due to published positive results from two of these trials. The incidence of major bleeding in these trials ranged from 0.6% to 2.7% (see Table 4).<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_Reft4"><BR>                           <caption>Table 4: Clinical Studies of Warfarin in Non-Rheumatic AF Patients<linkHtml href="#_Ref510 h * MERGEFORMAT" title="Error! Bookmark not defined.">Error! Bookmark not defined.</linkHtml>Error! Bookmark not defined.</caption><BR>                           <col width="12%"/><BR>                           <col width="18%"/><BR>                           <col width="13%"/><BR>                           <col width="9%"/><BR>                           <col width="8%"/><BR>                           <col width="16%"/><BR>                           <col width="8%"/><BR>                           <col width="18%"/><BR>                           <col width="13%"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Rrule Botrule Lrule Toprule "/><BR>                                 <th colspan="2" styleCode="Rrule Botrule Toprule "><BR>                                    <content styleCode="bold">N</content><BR>                                 </th><BR>                                 <th colspan="2" styleCode="Rrule Botrule Toprule "/><BR>                                 <th colspan="2" styleCode="Rrule Botrule Toprule "><BR>                                    <content styleCode="bold">Thromboembolism</content><BR>                                 </th><BR>                                 <th colspan="2" styleCode="Rrule Botrule Toprule "><BR>                                    <content styleCode="bold">% Major Bleeding</content><BR>                                 </th><BR>                              </tr><BR>                              <tr><BR>                                 <th styleCode="Rrule Lrule Botrule "><BR>                                    <content styleCode="bold">Study</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule "><BR>                                    <content styleCode="bold">Warfarin-Treated Patients</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule "><BR>                                    <content styleCode="bold">Control Patients</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule "><BR>                                    <content styleCode="bold">PT Ratio</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule "><BR>                                    <content styleCode="bold">INR</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule "><BR>                                    <content styleCode="bold">% Risk Reduction</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule "><BR>                                    <content styleCode="bold"><BR>                                       <content styleCode="italics">p</content>-value</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule "><BR>                                    <content styleCode="bold">Warfarin-Treated Patients</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule "><BR>                                    <content styleCode="bold">Control Patients</content><BR>                                 </th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Toprule Botrule "><BR>                                    <paragraph>AFASAK</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>335</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>336</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>1.5-2.0</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>2.8-4.2</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>60</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>0.027</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>0.6</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>0.0</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>SPAF</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>210</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 211</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 1.3-1.8</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 2.0-4.5</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 67</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 0.01</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 1.9</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 1.9</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>BAATAF</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>212</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 208</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 1.2-1.5</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 1.5-2.7</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 86</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> &lt;0.05</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 0.9</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 0.5</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>CAFA</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>187</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 191</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 1.3-1.6</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 2.0-3.0</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 45 </paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>0.25</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 2.7</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 0.5</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule Lrule "><BR>                                    <paragraph>SPINAF</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>260</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 265</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 1.2-1.5</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 1.4-2.8</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 79</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 0.001</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 2.3</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph> 1.5</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Trials in patients with both AF and mitral stenosis suggest a benefit from anticoagulation with warfarin sodium [see <BR>                              Dosage and Administration (2.2)<BR>                           ].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.2 Mechanical and Bioprosthetic Heart Valves<BR>                     <BR>                        In a prospective, randomized, open-label, positive-controlled study in 254 patients with mechanical prosthetic heart valves, the thromboembolic-free interval was found to be significantly greater in patients treated with warfarin alone compared with dipyridamole/aspirin-treated patients (p<0.005) and pentoxifylline/aspirin-treated patients (p<0.05). The results of this study are presented in Table 5.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_Reft5"><BR>                           <caption>Table 5: Prospective, Randomized, Open-Label, Positive-Controlled Clinical Study of Warfarin in Patients with Mechanical Prosthetic Heart Valves</caption><BR>                           <col width="20%"/><BR>                           <col width="12%"/><BR>                           <col width="16%"/><BR>                           <col width="16%"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Rrule Botrule Lrule Toprule "/><BR>                                 <th colspan="3" styleCode="Rrule Botrule Toprule "><BR>                                    <content styleCode="bold">Patients Treated With</content><BR>                                 </th><BR>                              </tr><BR>                              <tr><BR>                                 <th styleCode="Rrule Lrule Botrule "><BR>                                    <content styleCode="bold">Event</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule "><BR>                                    <content styleCode="bold">Warfarin</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule "><BR>                                    <content styleCode="bold">Dipyridamole/</content><BR>                                    <br/><BR>                                    <content styleCode="bold">Aspirin</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule "><BR>                                    <content styleCode="bold">Pentoxifylline/</content><BR>                                    <br/><BR>                                    <content styleCode="bold">Aspirin</content><BR>                                 </th><BR>                              </tr><BR>                           </thead><BR>                           <tfoot><BR>                              <tr><BR>                                 <td align="left" colspan="4" styleCode="Botrule" valign="top">py= patient years</td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Toprule Botrule "><BR>                                    <paragraph>Thromboembolism</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>2.2/100 py</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>8.6/100 py</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>7.9/100 py</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule Lrule "><BR>                                    <paragraph>Major Bleeding</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>2.5/100 py</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>0.0/100 py</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>0.9/100 py</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>In a prospective, open-label, clinical study comparing moderate (INR 2.65) vs. high intensity (INR 9.0) warfarin therapies in 258 patients with mechanical prosthetic heart valves, thromboembolism occurred with similar frequency in the two groups (4.0 and 3.7 events per 100 patient years, respectively). Major bleeding was more common in the high intensity group. The results of this study are presented in Table 6.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_Reft6"><BR>                           <caption>Table 6: Prospective, Open-Label Clinical Study of Warfarin in Patients with Mechanical Prosthetic Heart Valves</caption><BR>                           <col width="20%"/><BR>                           <col width="40%"/><BR>                           <col width="44%"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Rrule Botrule Lrule Toprule "><BR>                                    <content styleCode="bold">Event</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule Toprule "><BR>                                    <content styleCode="bold">Moderate Warfarin Therapy INR 2.65</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule Toprule "><BR>                                    <content styleCode="bold">High Intensity Warfarin Therapy INR 9.0</content><BR>                                 </th><BR>                              </tr><BR>                           </thead><BR>                           <tfoot><BR>                              <tr><BR>                                 <td align="left" colspan="7" styleCode="Botrule" valign="top">py= patient years</td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Toprule Botrule "><BR>                                    <paragraph>Thromboembolism</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>4.0/100 py</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>3.7/100 py</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule Lrule "><BR>                                    <paragraph>Major Bleeding</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>0.95/100 py</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>2.1/100 py</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>In a randomized trial in 210 patients comparing two intensities of warfarin therapy (INR 2.0-2.25 vs. INR 2.5-4.0) for a three-month period following tissue heart valve replacement, thromboembolism occurred with similar frequency in the two groups (major embolic events 2.0% vs. 1.9%, respectively, and minor embolic events 10.8% vs. 10.2%, respectively). Major hemorrhages occurred in 4.6% of patients in the higher intensity INR group compared to zero in the lower intensity INR group.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.3 Myocardial Infarction<BR>                     <BR>                        WARIS (The Warfarin Re-Infarction Study) was a double-blind, randomized study of 1214 patients 2 to 4 weeks post-infarction treated with warfarin to a target INR of 2.8 to 4.8. The primary endpoint was a composite of total mortality and recurrent infarction. A secondary endpoint of cerebrovascular events was assessed. Mean follow-up of the patients was 37 months. The results for each endpoint separately, including an analysis of vascular death, are provided in Table 7:<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_Reft7"><BR>                           <caption>Table 7: WARIS &#8211; Endpoint Analysis of Separate Events</caption><BR>                           <col width="33%"/><BR>                           <col width="17%"/><BR>                           <col width="18%"/><BR>                           <col width="18%"/><BR>                           <col width="20%"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Rrule Botrule Lrule Toprule "><BR>                                    <content styleCode="bold">Event</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule Toprule "><BR>                                    <content styleCode="bold">Warfarin</content><BR>                                    <br/><BR>                                    <content styleCode="bold">(N=607)</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule Toprule "><BR>                                    <content styleCode="bold">Placebo</content><BR>                                    <br/><BR>                                    <content styleCode="bold">(N=607)</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule Toprule "><BR>                                    <content styleCode="bold">RR (95% CI)</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule Toprule "><BR>                                    <content styleCode="bold">% Risk Reduction</content><BR>                                    <br/><BR>                                    <content styleCode="bold">(<content styleCode="italics">p</content>-value)</content><BR>                                 </th><BR>                              </tr><BR>                           </thead><BR>                           <tfoot><BR>                              <tr><BR>                                 <td align="left" colspan="5" styleCode="Botrule" valign="top">RR=Relative risk; Risk reduction=(1-RR); CI=Confidence interval; MI=Myocardial infarction; py=patient years</td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Toprule Botrule "><BR>                                    <paragraph>Total Patient Years of Follow-up</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>2018</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>1944</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Toprule Botrule "/><BR>                                 <td styleCode="Rrule Toprule Botrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Total Mortality</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule "><BR>                                    <paragraph>94 (4.7/100 py)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule "><BR>                                    <paragraph>123 (6.3/100 py)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule "><BR>                                    <paragraph>0.76 (0.60, 0.97)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule "><BR>                                    <paragraph>24 (p=0.030)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>&#160;&#160;Vascular Death</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>82 (4.1/100 py)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>105 (5.4/100 py)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>0.78 (0.60, 1.02)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>22 (p=0.068)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Recurrent MI</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>82 (4.1/100 py)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>124 (6.4/100 py)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>0.66 (0.51, 0.85)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>34 (p=0.001)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule Lrule "><BR>                                    <paragraph>Cerebrovascular Event</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>20 (1.0/100 py)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>44 (2.3/100 py)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>0.46 (0.28, 0.75)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>54 (p=0.002)</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>WARIS II (The Warfarin, Aspirin, Re-Infarction Study) was an open-label, randomized study of 3630 patients hospitalized for acute myocardial infarction treated with warfarin to a target INR 2.8 to 4.2, aspirin 160 mg per day, or warfarin to a target INR 2.0 to 2.5 plus aspirin 75 mg per day prior to hospital discharge. The primary endpoint was a composite of death, nonfatal reinfarction, or thromboembolic stroke. The mean duration of observation was approximately 4 years. The results for WARIS II are provided in the Table 8.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_Reft8"><BR>                           <caption>Table 8: WARIS II &#8211; Distribution of Events According to Treatment Group</caption><BR>                           <col width="44%"/><BR>                           <col width="11%"/><BR>                           <col width="12%"/><BR>                           <col width="23%"/><BR>                           <col width="17%"/><BR>                           <col width="9%"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Rrule Botrule Lrule Toprule "><BR>                                    <content styleCode="bold">Event</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule Toprule "><BR>                                    <content styleCode="bold">Aspirin</content><BR>                                    <br/><BR>                                    <content styleCode="bold">(N=1206)</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule Toprule "><BR>                                    <content styleCode="bold">Warfarin</content><BR>                                    <br/><BR>                                    <content styleCode="bold">(N=1216)</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule Toprule "><BR>                                    <content styleCode="bold">Aspirin plus Warfarin</content><BR>                                    <br/><BR>                                    <content styleCode="bold">(N=1208)</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule Toprule "><BR>                                    <content styleCode="bold">Rate Ratio</content><BR>                                    <br/><BR>                                    <content styleCode="bold">(95% CI)</content><BR>                                 </th><BR>                                 <th styleCode="Rrule Botrule Toprule "><BR>                                    <content styleCode="bold"><BR>                                       <content styleCode="italics">p</content>-value</content><BR>                                 </th><BR>                              </tr><BR>                           </thead><BR>                           <tfoot><BR>                              <tr><BR>                                 <td align="left" colspan="11" styleCode="Botrule" valign="top">CI=confidence interval</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" colspan="11" styleCode="Botrule" valign="top">ND=not determined</td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Toprule Botrule "/><BR>                                 <td colspan="3" styleCode="Rrule Toprule Botrule "><BR>                                    <paragraph>No. of Events</paragraph><BR>                                 </td><BR>                                 <td colspan="2" styleCode="Rrule Toprule Botrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Major Bleeding<linkHtml href="#_Ref510 h * MERGEFORMAT" title="Error! Bookmark not defined.">Error! Bookmark not defined.</linkHtml><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>8</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>33</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>28</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>3.35<footnote ID="_Refft8.1">The rate ratio is for aspirin plus warfarin as compared with aspirin.</footnote> (ND)<br/>4.00<footnote ID="_Refft8.2">The rate ratio is for warfarin as compared with aspirin.</footnote> (ND)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>ND<br/>ND</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Minor Bleeding<linkHtml href="#_Ref510 h * MERGEFORMAT" title="Error! Bookmark not defined.">Error! Bookmark not defined.</linkHtml><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>39</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>103</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>133</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>3.21<footnoteRef IDREF="_Refft8.1"/> (ND)<br/>2.55<footnoteRef IDREF="_Refft8.2"/> (ND)</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>ND<br/>ND</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Composite<br/>Endpoints<linkHtml href="#_Ref510 h * MERGEFORMAT" title="Error! Bookmark not defined.">Error! Bookmark not defined.</linkHtml><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>241</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>203</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>181</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>0.81 (0.69-0.95)<footnoteRef IDREF="_Refft8.1"/><BR>                                       <br/>0.71 (0.60-0.83)<footnoteRef IDREF="_Refft8.2"/><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>0.03<br/>0.001</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>&#160;&#160;Reinfarction</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>117</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>90</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>69</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>0.56 (0.41-0.78)<footnoteRef IDREF="_Refft8.1"/><BR>                                       <br/>0.74 (0.55-0.98)<footnoteRef IDREF="_Refft8.2"/><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>&lt;0.001<br/>0.03</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>&#160;&#160;Thromboembolic<br/>&#160;&#160;Stroke</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>32</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>17</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>17</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>0.52 (0.28-0.98)<footnoteRef IDREF="_Refft8.1"/><BR>                                       <br/>0.52 (0.28-0.97)<footnoteRef IDREF="_Refft8.2"/><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>0.03<br/>0.03</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule Lrule "><BR>                                    <paragraph>&#160;&#160;Death</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>92</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>96</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>95</paragraph><BR>                                 </td><BR>                                 <td styleCode="Rrule Botrule "/><BR>                                 <td styleCode="Rrule Botrule "><BR>                                    <paragraph>0.82</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>There were approximately four times as many major bleeding episodes in the two groups receiving warfarin than in the group receiving aspirin alone. Major bleeding episodes were not more frequent among patients receiving aspirin plus warfarin than among those receiving warfarin alone, but the incidence of minor bleeding episodes was higher in the combined therapy group.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>